Gyre Therapeutics, Inc. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
Gyre Therapeutics, Inc. (GYRE) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $358.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-07
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $358.00K.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $529.00K.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $172.00K.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $339.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $358.00K 10-Q · filed 2026-08-07 |
| 2026-03-31 | $529.00K 10-Q · filed 2026-05-08 |
| 2025-09-30 | $172.00K 10-Q · filed 2025-11-07 |
| 2025-06-30 | $339.00K 10-Q · filed 2025-08-11 |
| 2025-03-31 | $502.00K 10-Q · filed 2025-05-09 |
| 2024-09-30 | $9.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $17.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $26.00K 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |